FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079697277> ?p ?o ?g. }

• W2079697277 endingPage "141" @default.
• W2079697277 startingPage "141" @default.
• W2079697277 abstract "Herpes virus infections impose considerable morbidity in immunocompetent patients, with 22% of adults in developed countries having been infected with herpes simplex virus 2 (HSV-2) and four cases per 1000 individuals of symptomatic varicella zoster virus (VZV) infections estimated per year.1,2 Symptoms from both HSV and VZV can be effectively reduced with acyclovir therapy. More recently valaciclovir (GlaxoSmithKline, Brentford, London, UK) and famciclovir (Novartis, Basel, Switzerland) have shown similar efficacy in these conditions, with more favourable dosing schedules than acyclovir.3–6 The usage of these two drugs imposes a considerable financial burden on the public healthcare system, with initial treatment courses for HSV costing $A104.51 for valaciclovir and $A135.79 for famciclovir compared to $A89.31 for acyclovir – see http://www.pbs.gov. au/html/healthpro/search/ (accessed 26 April 2007). The Australian Health Insurance Commission spent $A27 816 155 and $A41 761 426 on famciclovir and valaciclovir respectively in the last financial year for HVS-2 and VZV management – see http://www.medicareaustralia.gov.au/statistics/ (accessed 26 April 2007). We therefore sought to determine if there was a perception of differential efficacy between these two commonly prescribed drugs and to determine which clinical characteristics might influence prescribing. In September 2003, an attitudinal survey was undertaken involving 632 metropolitan based primary care clinicians across Australia. The survey questions were prepared by the authors based on published clinical variables that might influence treatment responses, with the survey delivered to clinicians by product representatives from Novartis. The following research questions were asked: ‘Did the clinician believe that either famciclovir or valaciclovir had greater efficacy in certain patients?’ and ‘If so, what patient characteristics were thought to account for this difference (e.g. age, gender, number of episodes, severity or others)?’ This question was asked separately for patients with genital herpes and herpes zoster. Responses were collected by the product representatives within the following 2 weeks and forwarded to the authors for analysis." @default.
• W2079697277 created "2016-06-24" @default.
• W2079697277 creator A5018068497 @default.
• W2079697277 creator A5060359748 @default.
• W2079697277 date "2007-01-01" @default.
• W2079697277 modified "2023-09-27" @default.
• W2079697277 title "Famciclovir or valaciclovir in the management of herpes simplex and varicella zoster infections: an attitudinal survey of clinician perceptions of differential activity" @default.
• W2079697277 cites W1970118148 @default.
• W2079697277 cites W1980914468 @default.
• W2079697277 cites W2033484209 @default.
• W2079697277 cites W2154714320 @default.
• W2079697277 cites W2155950783 @default.
• W2079697277 cites W2158678799 @default.
• W2079697277 cites W2334917064 @default.
• W2079697277 doi "https://doi.org/10.1071/sh06060" @default.
• W2079697277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17524295" @default.
• W2079697277 hasPublicationYear "2007" @default.
• W2079697277 type Work @default.
• W2079697277 sameAs 2079697277 @default.
• W2079697277 citedByCount "0" @default.
• W2079697277 crossrefType "journal-article" @default.
• W2079697277 hasAuthorship W2079697277A5018068497 @default.
• W2079697277 hasAuthorship W2079697277A5060359748 @default.
• W2079697277 hasConcept C159047783 @default.
• W2079697277 hasConcept C16005928 @default.
• W2079697277 hasConcept C2522874641 @default.
• W2079697277 hasConcept C2776159415 @default.
• W2079697277 hasConcept C2776409557 @default.
• W2079697277 hasConcept C2776723293 @default.
• W2079697277 hasConcept C2780452071 @default.
• W2079697277 hasConcept C2780727368 @default.
• W2079697277 hasConcept C3013748606 @default.
• W2079697277 hasConcept C71924100 @default.
• W2079697277 hasConceptScore W2079697277C159047783 @default.
• W2079697277 hasConceptScore W2079697277C16005928 @default.
• W2079697277 hasConceptScore W2079697277C2522874641 @default.
• W2079697277 hasConceptScore W2079697277C2776159415 @default.
• W2079697277 hasConceptScore W2079697277C2776409557 @default.
• W2079697277 hasConceptScore W2079697277C2776723293 @default.
• W2079697277 hasConceptScore W2079697277C2780452071 @default.
• W2079697277 hasConceptScore W2079697277C2780727368 @default.
• W2079697277 hasConceptScore W2079697277C3013748606 @default.
• W2079697277 hasConceptScore W2079697277C71924100 @default.
• W2079697277 hasIssue "2" @default.
• W2079697277 hasLocation W20796972771 @default.
• W2079697277 hasLocation W20796972772 @default.
• W2079697277 hasOpenAccess W2079697277 @default.
• W2079697277 hasPrimaryLocation W20796972771 @default.
• W2079697277 hasRelatedWork W1750847649 @default.
• W2079697277 hasRelatedWork W2003370236 @default.
• W2079697277 hasRelatedWork W2057088834 @default.
• W2079697277 hasRelatedWork W2071736852 @default.
• W2079697277 hasRelatedWork W2104469521 @default.
• W2079697277 hasRelatedWork W2132236918 @default.
• W2079697277 hasRelatedWork W2225331039 @default.
• W2079697277 hasRelatedWork W2425409207 @default.
• W2079697277 hasRelatedWork W2551604655 @default.
• W2079697277 hasRelatedWork W3214977168 @default.
• W2079697277 hasVolume "4" @default.
• W2079697277 isParatext "false" @default.
• W2079697277 isRetracted "false" @default.
• W2079697277 magId "2079697277" @default.
• W2079697277 workType "article" @default.